論文 - 肥田　時征

Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.

Shiori Kamiya, Junji Kato, Takafumi Kamiya, Toshiharu Yamashita, Yasuyuki Sumikawa, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Hitomi Takahashi, Masahide Sawada, Terufumi Kubo, Toshihiko Torigoe, Hisashi Uhara

Asia-Pacific journal of clinical oncology   16 ( 2 ) e108-e112  2020年04月  [査読有り]  [国際誌]

　概要を見る

AIM: To clarify the relationship between programmed cell death ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and clinicopathological variables. METHODS: We examined PD-L1 expression in tumor cells (TCs) and tumor infiltrating immune cells (ICs) in 46 cases of cSCC by immunohistochemistry. In each case, we employed two methods-intensity and proportion scores-to evaluate PD-L1 expression in TCs. For the evaluation of PD-L1 expression in ICs, only the proportion score was used. Association between PD-L1 expression and clinicopathological variables was analyzed using Fisher's exact test. RESULTS: High intensity scores in TCs were observed in 18 of the 46 cases (39.1%) and low intensity scores were observed in 28 cases (60.9%). Applying the proportions, using cut-off values of ≥1% and 50%, positive scores in TCs were observed in 36 (78.3%) and 20 cases (43.5%), respectively. PD-L1-positive ICs were observed in 29 (63%) and seven cases (15.2%), using cut-off values of ≥1% and 10%, respectively. The high intensity scores in TCs correlated with lymph node metastasis (P = 0.008) and female gender (P = 0.017), although positive proportions in TCs or ICs were not significantly related to lymph node metastasis. A multivariate analysis showed that high intensity of PD-L1 expression in TCs was an independent risk factor for lymph node metastasis. CONCLUSIONS: The results suggested that high intensity of PD-L1 expression in TCs is associated with lymph node metastasis in cSCC.

DOI PubMed

Prognostic Factors and Long-Term Efficacy of Tonsillectomy in 17 Patients with Pustulotic Arthro-Osteitis.

Yuji Kan, Yasuyuki Sumikawa, Tokimasa Hida, Saeko Ajiki, Hisashi Uhara

The Eurasian journal of medicine   52 ( 1 ) 103 - 105  2020年02月  [査読有り]  [国際誌]

　概要を見る

In this case study, we aimed to evaluate the disease condition of patients with pustulotic arthro-osteitis (PAO) at 36-month post-tonsillectomy. A retrospective analysis of the cases of 17 patients with PAO who were resistant to initial systemic treatments and underwent tonsillectomy at our hospital in 2006-2016 was conducted. The patients' disease condition at 1-, 24-, and 36-month post-tonsillectomy was assessed by the visual analog scale (VAS) score for osteoarthropathic pain, the disease duration, the area of palmoplantar lesions, and the Palmoplantar Pustular Psoriasis Area Severity Index (ppPASI). In the minimum follow-up of 36-month post-tonsillectomy in 17 patients, the median ppPASI and VAS scores decreased from 12 to 1 and from 80 to 20, respectively. Thirteen patients with ≥70% improvement in their VAS scores maintained the same good condition after ≥36 months, whereas four patients with <70% improvement in their VAS scores did not show remarkable improvement after that time point. Furthermore, we found that the improvement in VAS score was not associated with the disease duration or the patients' pre-tonsillectomy ppPASI values. Tonsillectomy might be an alternative treatment option for patients with PAO. Long-term efficacy against pain can be predicted by evaluating a patient's improvement at 1-month post-tonsillectomy.

DOI PubMed

Significance of 5‐S‐Cysteinyldopa as a Marker for Melanoma

Kazumasa Wakamatsu, Satoshi Fukushima, Akane Minagawa, Toshikazu Omodaka, Tokimasa Hida, Naohito Hatta, Minoru Takata, Hisashi Uhara, Ryuhei Okuyama, Hironobu Ihn

International Journal of Molecular Sciences   21 ( 2 ) 432  2020年01月  [査読有り]  [国際誌]

　概要を見る

Melanoma is one of the most lethal and malignant cancers and its incidence is increasing worldwide, and Japan is not an exception. Although there are numerous therapeutic options for melanoma, the prognosis is still poor once it has metastasized. The main concern after removal of a primary melanoma is whether it has metastasized, and early detection of metastatic melanoma would be effective in improving the prognosis of patients. Thus, it is very important to identify reliable methods to detect metastases as early as possible. Although many prognostic biomarkers (mainly for metastases) of melanoma have been reported, there are very few effective for an early diagnosis. Serum and urinary biomarkers for melanoma diagnosis have especially received great interest because of the relative ease of sample collection and handling. Several serum and urinary biomarkers appear to have significant potential both as prognostic indicators and as targets for future therapeutic methods, but still there are no efficient serum and urinary biomarkers for early detection, accurate diagnosis and prognosis, efficient monitoring of the disease and reliable prediction of survival and recurrence. Levels of 5-S-cysteinyldopa (5SCD) in the serum or urine as biomarkers of melanoma have been found to be significantly elevated earlier and to reflect melanoma progression better than physical examinations, laboratory tests and imaging techniques, such as scintigraphy and echography. With recent developments in the treatment of melanoma, studies reporting combinations of 5SCD levels and new applications for the treatment of melanoma are gradually increasing. This review summarizes the usefulness of 5SCD, the most widely used and well-known melanoma marker in the serum and urine, compares 5SCD and other useful markers, and finally its application to other fields.

DOI PubMed

Current clinical issue of skin lesions in patients with inflammatory bowel disease.

Tomoya Iida, Tokimasa Hida, Minoru Matsuura, Hisashi Uhara, Hiroshi Nakase

Clinical journal of gastroenterology   12 ( 6 ) 501 - 510  2019年12月  [査読有り]  [国内誌]

　概要を見る

Inflammatory bowel disease (IBD) is associated with a number of extraintestinal complications, including skin lesions. Most reports have shown that skin lesions are found in 10-15% of IBD cases, although this depends on the definition of skin lesions. The representative skin lesions in patients with IBD are erythema nodosum, pyoderma gangrenosum, Sweet's syndrome, and so on. These lesions are often associated with IBD progression, and intestinal lesions in particular require appropriate treatment. Recently, another clinical issue regarding skin lesions in patients with IBD, a so-called paradoxical reaction, during the treatment with anti-tumor necrosis factor (TNF)-α agents has emerged. These reactions are termed paradoxical reactions because the skin lesions sometimes resemble psoriasis, although the anti-TNF-α agents have been historically used to treat psoriasis. Paradoxical reactions are reportedly found in approximately 5-10% of patients using anti-TNF-α agents and are no longer rare. Now that the use of biologics is at its culmination, reports regarding paradoxical reactions are predicted to increase in number; thus, we must recognize skin lesions with IBD patients including this type of adverse events and manage them appropriately while consulting with dermatologists.

DOI PubMed

Durable response after cessation of anti-programmed death 1 therapy in four melanoma patients.

Toshiya Handa, Junji Kato, Yasuyuki Sumikawa, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Masahide Sawada, Mao Fujioka, Tomoyuki Minowa, Yoshiyuki Matsui, Hisashi Uhara

The Journal of dermatology   46 ( 12 ) e461-e462 - e462  2019年12月  [査読有り]  [国際誌]

DOI PubMed

Docetaxel therapy for classic Kaposi's sarcoma.

Yuna Hosokawa, Junji Kato, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Masahide Sawada, Hiroshi Sasaki, Yoshiyuki Matsui, Toshiya Handa, Hisashi Uhara

Asia-Pacific journal of clinical oncology   15 ( 3 ) 181 - 182  2019年06月  [査読有り]  [国際誌]

DOI PubMed

Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma.

Junji Kato, Tokimasa Hida, Masanori Someya, Sayuri Sato, Masahide Sawada, Kohei Horimoto, Mao Fujioka, Tomoyuki Minowa, Yoshiyuki Matsui, Takaaki Tsuchiya, Mio Kitagawa, Kensei Nakata, Koh-Ichi Sakata, Toshihiko Torigoe, Hisashi Uhara

The Journal of dermatology   46 ( 4 ) 328 - 333  2019年04月  [査読有り]  [国際誌]

　概要を見る

Some studies showed that clinical response to immune check point inhibitors is lower in acral and mucosal melanoma than in cutaneous melanoma. Although the synergistic effect of radiotherapy (RT) and ipilimumab has been reported in patients with brain metastasis, the efficacy of combined RT and anti-programmed death 1 (PD-1) therapy for acral and mucosal melanoma is unclear. The present study aimed to evaluate the efficacy of combined RT and anti-PD-1 therapy for acral and mucosal melanoma. We retrospectively analyzed patients with acral or mucosal melanoma who were treated with anti-PD-1 and RT at Sapporo Medical University Hospital. In 10 patients (acral, 3; mucosal, 7), the response rate (RR) and the disease control rate (DCR) were 40% and 60%, respectively. As regards mucosal melanoma, four of the seven patients had achieved complete response + partial response, and three had progressive disease (RR = 57.1%). Meanwhile, two of the three patients with acral melanoma had stable disease and one had progressive disease (RR and DCR were 0% and 66.6%, respectively). Except for the patients treated with palliative RT for bone metastasis in the present study, the RR was 50% (4/8 patients), and the DCR was 75% (6/8 patients). Vitiligo developed after RT in five (50%) patients at a median duration of 2 months after RT. The clinical response and the high occurrence of vitiligo suggest that the combination of RT and anti-PD-1 therapy could be effective in some patients with mucosal melanoma.

DOI PubMed

Xeroderma pigmentosum group D: Report of a novel combination of ERCC2 variations and its phenotype.

Tokimasa Hida, Masae Okura, Keiju Kobayashi, Toshiharu Yamashita, Chikako Nishigori, Hisashi Uhara

The Journal of dermatology   46 ( 3 ) e81-e82 - e82  2019年03月  [査読有り]  [国際誌]

DOI PubMed

A case of childhood-onset cutaneous mastocytosis with loss of wild-type KIT allele.

Hida T, Okura M, Kamiya T, Yamamoto M, Hori T, Uhara H

Journal of the European Academy of Dermatology and Venereology : JEADV    2019年02月  [査読有り]

DOI PubMed

Successful rechallenge with nivolumab therapy after radiotherapy in mucosal melanoma.

Junji Kato, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Keiju Kobayashi, Masahide Sawada, Mao Fujioka, Takaaki Tsuchiya, Masanori Someya, Hisashi Uhara

The Journal of dermatology   46 ( 2 ) e72-e73 - e73  2019年02月  [査読有り]  [国際誌]

DOI PubMed

Halo formations around senile hemangiomas in diffuse plane normolipemic xanthomatosis associated with monoclonal gammopathy.

Tokimasa Hida, Hiroki Takahashi, Kohichi Takada, Hisashi Uhara

JAAD case reports   4 ( 10 ) 1034 - 1036  2018年11月  [査読有り]  [国際誌]

DOI PubMed

Transient hypogammaglobulinemia of infancy with no evidence of immunodeficiency other than atopic dermatitis: A case report and review of literature

Minowa T, Sumikawa Y, Hida T, Uhara H

J Cutan Immunol Allergy ( JOHN WILEY & SONS LTD )  1 ( 5 ) 174 - 175  2018年11月  [査読有り]

DOI

Nevus cells of cardiofaciocutaneous syndrome bear BRAF germ-line and somatic double mutations.

Tokimasa Hida, Sayuri Sato, Masae Okura, Hisashi Uhara

European journal of dermatology : EJD   28 ( 5 ) 704 - 705  2018年10月  [査読有り]  [国際誌]

DOI PubMed

Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with anti-programmed death-1.

Tomoyuki Minowa, Junji Kato, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Masahide Sawada, Hisashi Uhara

European journal of dermatology : EJD   28 ( 5 ) 705 - 707  2018年10月  [査読有り]  [国際誌]

DOI PubMed

A case of subepidermal autoimmune bullous disease with autoantibodies against 200 and 290-kDa antigens

M. Sawada, T. Hida, H. Ujiie, H. Iwata, H. Uhara

Journal of the European Academy of Dermatology and Venereology   32 ( 9 ) e354 - e355  2018年09月  [査読有り]

担当区分：   責任著者

DOI PubMed

Novel COL7A1 mutation in a family with bullous dermolysis of the newborn: Phenotypic variability associated with a COL7A1 mutation within the same family.

Shota Takashima, Satoru Shinkuma, Yasuyuki Fujita, Ken Natsuga, Toshifumi Nomura, Tokimasa Hida, Shuku Ishikawa, Hideki Nakamura, Riichiro Abe, Hiroshi Shimizu

The Journal of dermatology   45 ( 9 ) e260-e261 - e261  2018年09月  [査読有り]  [国際誌]

DOI PubMed

Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.

Tomoyuki Minowa, Junji Kato, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Masahide Sawada, Hisashi Uhara

The Journal of dermatology   45 ( 9 ) e250-e251 - e251  2018年09月  [査読有り]  [国際誌]

DOI PubMed

Cytokeratin 19 expression is a risk factor for metastasis in cutaneous squamous cell carcinoma

J. Kato, T. Hida, S. Sugita, T. Hasegawa, S. Kamiya, K. Horimoto, S. Sato, M. Sawada, H. Uhara

Journal of the European Academy of Dermatology and Venereology ( Blackwell Publishing Ltd )  32 ( 7 ) e299 - e301  2018年07月  [査読有り]

DOI

Granulocyte colony-stimulating factor-producing melanoma treated with the combination of dabrafenib and trametinib

T. Minowa, J. Kato, T. Hida, K. Horimoto, S. Sato, M. Sawada, H. Takahashi, H. Uhara

International Journal of Dermatology ( Blackwell Publishing Ltd )  57 ( 7 ) e31 - e33  2018年07月  [査読有り]

DOI PubMed

Cytokeratin 19 expression as a risk factor for metastasis in cutaneous squamous cell carcinoma.

Uhara Hisashi, Kato Junji, Hida Tokimasa

JOURNAL OF CLINICAL ONCOLOGY   36 ( 15 )  2018年05月  [査読有り]

DOI